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Abstract
The prothrombotic nature of sickle cell disease (SCD) is evidenced by the chronically elevated
levels of almost all coagulation activation biomarkers, and an increased incidence of certain
thrombotic events, including venous thromboembolism. Numerous studies have attempted to
define the extent and elucidate the mechanism of the observed increase in thrombin generation in
SCD patients in vivo. In general, these studies were performed using thrombin generation assays
in platelet poor or platelet rich plasma and showed little difference in endogenous thrombin
potential between the SCD cohort and healthy matched controls. In SCD, erythrocytes and
monocytes have been demonstrated to exhibit procoagulant characteristics. Thus, the absence of
these cellular components in standard thrombin generation assays may fail to reflect global
hypercoagulability in the whole blood of patients with SCD. We were therefore surprised to see no
difference in net thrombin generation in tissue factor-initiated initiated clotting of whole blood
from patients with SCD. However, we are continuing to reconcile these seemingly disparate
observations by slight modifications of the whole blood model that include alternative coagulation
triggers and a re-examination of the net thrombin generation when the protein/protein S system is
simultaneously interrogated.
Approximately 1 in 625 African Americans are affected by sickle-cell disease (SCD) that is
characterized by vaso-occlusive manifestations (including pain crises) and multiple end
organ damage of varying severity [1]. Crises are generally ascribed to obstruction of the
microvasculature secondary to adhesion of sickled red blood cells (RBCs) and other
hematopoietic cellular elements. This process is followed by activation of coagulation and
inflammatory pathways, as evidenced by the observation that patients with SCD typically
manifest elevated plasma levels of thrombin–antithrombin (TAT) complexes, prothrombin
fragment 1.2 (F1.2), and D-dimer [2, 3]. Furthermore, decreased levels of natural
anticoagulant proteins, such as proteins C and S [4], as well as increased platelet activation
[5] and increased numbers of circulating activated endothelial cells and monocytes
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expressing tissue factor also contribute to a systemic hypercoagulable state [6]. RBC
sickling is central to the pathology of SCD. The repeated sickling and unsickling process as
RBCs navigate the microvasculature leads not only to abnormal phosphatidylserine (PS)
exposure, but also to an overall shortening of the RBC lifespan from ~120 to ~20 days. The
ischemia-reperfusion cycle results in systemic inflammation with activation of leukocytes
and endothelial cells. In turn, these events promote increased vessel wall permeability with
neutrophil adhesion/migration into the inflamed tissues. Inflammatory cells produce
cytokines including TNFα, IL-8 and IL-1β that activate vascular endothelial cells resulting
in up-regulation of cellular adhesion molecules including intercellular adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). This response further
enhances the adhesiveness of inflammatory cells, platelets and sickled RBCs to endothelium
[7]. These events collectively result in up-regulation of the idling threshold of thrombin
generation; this impression is further corroborated by the clinical evidence for increased
thrombotic events, such as venous thromboembolism (VTE) experienced by patients with
SCD [1].
Several in vitro and ex vivo methodologies have been employed to examine thrombin
generation potential in the peripheral blood of subjects with SCD. The most extensive
studies of hypercoagulability in SCD have utilized (platelet rich or platelet poor) plasma-
based thrombin generation assays. We recently summarized these data that have shown
disparate results amongst six different laboratories with no conclusive evidence to suggest
elevated thrombin generation potential in SCD by this approach [6]. The lack of
standardization in plasma sample preparation and notorious inter-laboratory variability of
these assays may have accounted for the inconsistent findings. Additionally, none of these
studies specifically interrogated the protein C pathway (e.g. by addition of
thrombomodulin). However, another report, not included in this study, did show activated
protein C resistance when thrombomodulin was implemented [8]. Finally, the lack of
erythrocytes and leucocytes in these assays likely fails to reflect the global
hypercoagulability that may be present in whole blood in SCD, since almost all of the
cellular components display procoagulant characteristics [9, 10].
One candidate contributor to thrombosis in SCD is the loss of normal membrane
phospholipid asymmetry on sickled RBCs. Disruption of membrane phospholipid
asymmetry results from repeated hypoxia-induced sickling and unsickling [11]. The
exposure of anionic PS on the outer membrane results in a sub-population of prothrombotic
RBCs that support the assembly of enzymatic clotting reactions [12, 13]. Only two studies
have specifically examined thrombin generation in the whole blood of patients with SCD.
The first of these was by Yee et al. in 2005 utilizing thromboelastometry [14]. Compared to
a group of healthy race-matched controls, the SCD cohort displayed a hypercoagulable state
characterized by decreased R time coupled with an increase in the α angle. This study also
found that blood obtained from HbSS patients during acute painful crises exhibited an
increased maximum amplitude and coagulation index compared with HbSS patients at
baseline. More recently, our laboratory evaluated thrombin generation in the whole blood of
a small cohort of individuals with HbSS and race-matched controls [15]. Our methodology
differed from that of TEG in that we measured thrombin generation as a function of its
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inhibition by its main stoichiometric inhibitor, antithrombin. Interestingly, the overall extent
of α-thrombin-antithrombin (αTAT) generation did not differ significantly between the two
groups; however, the rates of αTAT generation and consumption of prothrombin were
increased in the HbSS cohort relative to controls. We also measured the rate of production
of meizothrombin-antithrombin (mTAT) complexes that is indicative of thrombin generation
on non-platelet surfaces, including red cells. The maximum level of mTAT produced in the
HbSS cohort was approximately double that observed in the controls. Furthermore, we
measured PS exposure on individual patient’s RBC population by flow cytometry, and noted
that the rate of mTAT formation was directly proportional to the number of PS-expressing
RBCs for each group. Although there was no statistical difference in the absolute αTAT
levels between the two groups, the higher rate of mIIa generation and prothrombin
consumption observed in the HbSS patients, together with their much lower RBC numbers,
suggests that in SCD, a much higher proportion of thrombin is generated on RBC surfaces.
The studies of TF-dependent thrombin generation outlined above suggest that only modest
differences exist between HbSS and healthy controls, regardless of the methodology.
However, coagulation may be activated through either the TF-mediated (extrinsic) or the
contact activation (intrinsic) pathways. It was shown many years ago that plasma levels of
the contact factors (FXII, prekallikrein and high molecular weight kininogen) are reduced in
patients with SCD, suggesting a consumptive process [16-18]. A recent study demonstrated
that platelet and RBC-derived microparticles can initiate thrombin generation through
FXIIa, presumably via a PS-mediated process [19]. Sickled RBCs not only shed
microparticles (MP), but share many of their procoagulant properties. Thus, the question
remains as to whether the increase in coagulation activation observed in SCD is initiated
primarily through the extrinsic or intrinsic pathway with red cells and their shed MPs
playing a key role in the latter. This possibility is further supported by other recent data from
our laboratory which suggest that in a model of human endotoxemia, MP-dependent
activation of coagulation is not mediated through the extrinsic pathway but rather through a
FXI-dependent mechanism [20]. It should be noted that these observations do not exclude
that cell-mediated activation of coagulation is dependent on tissue factor. Our current efforts
are directed at ex vivo examination of contact pathway mediated thrombin generation in the
whole blood of a larger cohort of individuals with SCD and race-matched controls. To
accomplish this, we are employing the in vitro whole blood assay, TEG and plasma-based
thrombin generation assays, both in the presence and absence of soluble thrombomodulin.
Alternatively, the in vitro whole blood assay can be augmented by the addition of an
endothelial monolayer which has also been shown to efficiently activate the protein C
pathway [21]. Contact activation in each case is accomplished via native blood clotting in
the absence of exogenous anticoagulants or extrinsic/intrinsic stimulators with thrombin
generation and FXI activation being assessed via TAT and FXIa-AT/FXIa-C1 Esterase
Inhibitor complex ELISA assays, respectively. Collectively, these tools will allow for a
more in-depth examination of intrinsically activated thrombin generation in the whole blood
of patients with sickle cell disease.
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